|Over a week ago|
Rani Therapeutics reports Q2 EPS (12c), consensus (18c) » 16:2509/1309/13/21
Reports Q2 revenue…
Reports Q2 revenue $1.96M, consensus $490,000. "This is an exciting phase for Rani following a successful IPO, which puts us in position to achieve our goals, including scaling and optimizing our manufacturing process, establishing the regulatory pathway for our capsule technology, and advancing our pipeline with clinical and development milestones," said Talat Imran, CEO of Rani Therapeutics. "We are committed to making oral biologics a reality, and we are looking forward to creating value along the way for both patients and shareholders."
Rani Therapeutics appoints Eric Groen as General Counsel » 08:1109/0909/09/21
Rani Therapeutics appointed Eric Groen as General Counsel. Groen Prior to joining Rani, Groen served in various domestic and international roles of increasing responsibility over nearly 20 years at Amgen. Most recently, he served as regional general counsel to Amgen's commercial business in Canada, Latin America, Middle East and Africa.
|Over a month ago|
Rani Therapeutics initiated with a Buy at BTIG » 07:4508/2508/25/21
BTIG analyst Robert…
BTIG analyst Robert Hazlett initiated coverage of Rani Therapeutics with a Buy rating and $24 price target. The company is "bringing the promise of broad-scale oral biologics to the fore", the analyst tells investors in a research note, stating that its most advanced program - RT-101 - has helped establish proof-of-principle for the RaniPill capsule technologies. Hazlett adds that he sees a billion dollar peak revenue potential for Rani's RT-102, RT-109, RT-105, and the diabetes molecules.
Rani Therapeutics initiated with Buy, $29 target at Canaccord » 07:1608/2508/25/21
Canaccord analyst Michelle Gilson initiated coverage of Rani Therapeutics with a Buy rating and $29 price target. The analyst says Rani shares offer investors an opportunity to gain exposure to a clinical-stage company developing a "broad platform technology poised to disrupt the field of pain-free, oral biologics delivery." RaniPill is a reasonably-sized robotic pill device that is swallowed and activated in the small intestine, where there are no sharp pain receptors and is differentiated from competitive oral delivery technologies by the high bioavailability achieved, Gilson As previously reported,
Rani Therapeutics initiated with a Buy at Canaccord » 07:0308/2508/25/21
Canaccord analyst Michelle Gilson initiated coverage of Rani Therapeutics with a Buy rating and $29 price target.
Rani Therapeutics initiated with a Buy at BofA » 07:4108/2408/24/21
BofA analyst Geoff…
BofA analyst Geoff Meacham initiated coverage of Rani Therapeutics with a Buy rating and $23 price target. Rani's approach in oral administration of injectable drugs is differentiated from competitors which have historically used molecular engineering of the reference drug as a strategy, the analyst tells investors in a research note. If the company is successful, it could "revolutionize" the delivery of complex biologics such as peptides and antibodies, Meacham adds, estimating its initial pipeline therapies providing more than $5B in peak sales.
Rani Therapeutics initiated with a Buy at Stifel » 06:2008/2408/24/21
Stifel analyst Annabel…
Stifel analyst Annabel Samimy initiated coverage of Rani Therapeutics with a Buy rating and $24 price target. Rani has a disruptive platform offering a technological, rather than pharmacological, approach to delivery, and Samimy thinks Rani has established a platform that generates value-driving catalysts and avenues for sustained growth, the analyst tells investors in a research note.
Rani Therapeutics initiated with an Overweight at Cantor Fitzgerald » 06:1508/2408/24/21
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Brandon Folkes initiated coverage of Rani Therapeutics with an Overweight rating and $23 price target.
Rani Therapeutics initiated with a Buy at BofA » 06:0508/2408/24/21
BofA initiated coverage…
BofA initiated coverage of Rani Therapeutics with a Buy rating and $23 price target.
Opening Day: Sportradar files for IPO after SPAC talks break off » 08:2708/2108/21/21
ARBK, ARBKF, PRCT, SRAD, QNIU, CMSL, SPRK, SCAN, AUTH, BLK, SPG, MS, GS, BCS, BAC, MXCT, RXST, TNYA, RANI, NUVL, ICVX, RSKD, OMGA, IMRX, INAB, HOOD, RLYB, ABVC
In a quiet week for IPOs,…